rebamipide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2360	90098-04-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: OPC-12759 rebamipide proamipide mucosta	Rebamipide is a mucosal protective agent and is postulated to increase gastric blood flow, prostaglandin biosynthesis and decrease free oxygen radicals. Molecular weight: 370.79 Formula: C19H15ClN2O4 CLOGP: 1.97 LIPINSKI: 0 HAC: 6 HDO: 3 TPSA: 95.50 ALOGS: -4.56 ROTB: 5

Molecule

Description

Molfile Inchi Smiles

Synonyms:

OPC-12759
rebamipide
proamipide
mucosta

Rebamipide is a mucosal protective agent and is postulated to increase gastric blood flow, prostaglandin biosynthesis and decrease free oxygen radicals.

Molecular weight: 370.79
Formula: C19H15ClN2O4
CLOGP: 1.97
LIPINSKI: 0
HAC: 6
HDO: 3
TPSA: 95.50
ALOGS: -4.56
ROTB: 5

Drug dosage:

Dose	Unit	Route
0.30	g	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Hosey CM, Chan R, Benet LZ
S (Water solubility)	0.03 mg/mL	Bocci G, Oprea TI, Benet LZ

Showing 1 to 2 of 2 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Sept. 26, 2011	PMDA

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatic function abnormal	252.55	18.26	123	10365	37019	63441515
Platelet count decreased	247.96	18.26	182	10306	115940	63362594
Interstitial lung disease	234.74	18.26	139	10349	61769	63416765
Drug eruption	115.38	18.26	67	10421	28627	63449907
Drug ineffective	94.67	18.26	28	10460	1044737	62433797
White blood cell count decreased	91.96	18.26	114	10374	138990	63339544
Malignant neoplasm progression	88.50	18.26	87	10401	82034	63396500
Spinal compression fracture	87.18	18.26	44	10444	14239	63464295
Liver disorder	85.74	18.26	71	10417	53616	63424918
Fatigue	85.64	18.26	21	10467	888007	62590527

Showing 1 to 10 of 72 entries

Previous1 2 3 4 5…8Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Interstitial lung disease	249.74	18.47	177	9293	65105	34882356
Hepatic function abnormal	199.52	18.47	133	9337	44230	34903231
Platelet count decreased	90.52	18.47	135	9335	119582	34827879
Disseminated intravascular coagulation	71.50	18.47	54	9416	21762	34925699
Malignant neoplasm progression	70.39	18.47	102	9368	87944	34859517
Cerebral infarction	68.70	18.47	58	9412	27397	34920064
Fatigue	63.34	18.47	12	9458	370641	34576820
Upper respiratory tract inflammation	59.18	18.47	21	9449	1723	34945738
Neutrophil count decreased	52.64	18.47	67	9403	51037	34896424
Decreased appetite	51.03	18.47	128	9342	166264	34781197

Showing 1 to 10 of 49 entries

Previous1 2 3 4 5Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Interstitial lung disease	465.71	15.69	314	20171	112286	79611617
Hepatic function abnormal	417.26	15.69	250	20235	72857	79651046
Platelet count decreased	312.77	15.69	313	20172	194351	79529552
Malignant neoplasm progression	162.22	15.69	187	20298	135803	79588100
Fatigue	143.56	15.69	32	20453	929695	78794208
Drug eruption	142.93	15.69	106	20379	43829	79680074
Cerebral infarction	134.87	15.69	104	20381	45572	79678331
White blood cell count decreased	132.83	15.69	200	20285	188088	79535815
Drug ineffective	120.87	15.69	64	20421	1080849	78643054
Disseminated intravascular coagulation	115.51	15.69	86	20399	35756	79688147

Showing 1 to 10 of 140 entries

Previous1 2 3 4 5…14Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	A02BX14	ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)
MeSH PA	D000897	Anti-Ulcer Agents
MeSH PA	D000975	Antioxidants
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D020011	Protective Agents

Showing 1 to 6 of 6 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Gastritis	indication	4556007	DOID:4029
Peptic ulcer	indication	13200003	DOID:750

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.32	acidic
pKa2	12.06	acidic
pKa3	13.42	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Cholecystokinin receptor type A	GPCR		CCKAR_RAT	AGONIST	IC50	4.40		IUPHAR

Showing 1 to 1 of 1 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
1172393005	SNOMEDCT_US
1172878003	SNOMEDCT_US
5042	PUBCHEM_CID
6454	INN_ID
871	IUPHAR_LIGAND_ID
C0069562	UMLSCUI
C052785	MESH_SUPPLEMENTAL_RECORD_UI
CHEBI:32090	CHEBI
CHEMBL1697771	ChEMBL_ID
D01121	KEGG_DRUG

Showing 1 to 10 of 12 entries

Previous1 2Next

Pharmaceutical products:

None